Navigation Links
Increased Usage of Mifeprex(R) Helps Slow Decline in Abortion Providers

~80% of Clinics Now Offer Mifeprex(R)

NEW YORK, Jan. 17 /PRNewswire/ -- The Guttmacher Institute announced today that use of Mifeprex(R) (the brand name for mifepristone) for early medication abortion increased substantially between 2000 and 2005. According to the report, approximately 78-81% of clinics now offer Mifeprex(R). The report also found that more than half of all known abortion providers are offering Mifeprex(R), a 70% increase from the first half of 2001. Additionally, these findings show that the increased number of Mifeprex(R) providers has helped to slow the overall decline in abortion providers. Since FDA approval of Mifeprex(R) in September 2000, more than 840,000 women in the United States have chosen Mifeprex(R) as a safe and effective, private option for ending early pregnancy.

Nearly 90% of abortions in the U.S. occur during the first trimester. In more recent years women having an abortion are able to do so earlier and earlier in the first trimester. According to Guttmacher, the proportion of providers offering very early medication or surgical abortions grew from 7% in 1993 to 40% in 2005. Mifeprex(R) allows women to act early, up to 7 weeks from the beginning of their last menstrual period. Currently, more than six in 10 abortions occur within the first 8 weeks of pregnancy.

Serious and sometimes fatal infections and bleeding occur very rarely following spontaneous, surgical, and medical abortions, including following Mifeprex(R) use. No causal relationship between the use of Mifeprex(R) and misoprostol and these events has been established. A high index of suspicion is needed to rule out serious and rarely fatal infections (e.g. Clostridium sordellii) and sepsis that can present without fever, bacteremia or significant findings on a pelvic exam, with or without abdominal pain, but with leukocytosis with a marked left shift, tachycardia, hemoconcentration, and general malaise.

Danco Laboratories, LLC is a women's health pharmaceutical company that has been granted an exclusive license from the Population Council to manufacture, market and distribute Mifeprex(R) in the United States.

For Prescribing Information, or more information about Mifeprex(R), please access the Mifeprex(R) web site at Or call the Mifeprex(R) hotline at 1-877-4 Early Option (1-877-432-7596).

The Guttmacher Institute's study, "Abortion in the United States: Incidence and Access to Services, 2005" is the most complete available data on the number of abortions and abortion providers in the U.S.

Media Contact:

Mendy Andresen


SOURCE Danco Laboratories, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Increased distance to physician associated with thicker skin cancer at diagnosis
2. Methamphetamine study suggests increased risk for HIV transmission
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Minorities more likely to have sleep durations associated with increased mortality
5. Teens who see more smoking in movies may have increased risk of becoming established smokers
6. Study shows adverse drug events reported to the FDA have significantly increased
7. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction
8. Maternal depression and controlling behavior associated with increased stress response in infants
9. BioProcessors Launches SimCell(TM) Services to Meet Increased Customer Demand
10. Both short and long sleep is associated with increased mortality
11. New Study Shows Lower Costs, Increased Consumer Engagement in Account-Based Health Plans
Post Your Comments:
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... According ... of obesity groups has filed a discrimination claim against the U.S. Department of Health ... in their Affordable Care Act (ACA) plans are breaking the clause in the law ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , one of ... iconic bottle has won top honors in Beverage World Magazine’s Global Packaging Design Awards, ... that it has been selected as a 2015 U.S.A. Taste Champion in the American ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... Growth ... in part due to decreases in utilization of hospital and nonhospital care, according to ... CompScope™ Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today ... Golden Bridge Business Awards under the New Products and Services category for its ... sample management software that helps labs organize data and track samples ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... -- Six months of adjunctive metformin therapy does not improve glycemic ... new research from T1D Exchange and funded by ... effect on measures of obesity, including weight and BMI. The ... of the American Medical Association , are from the largest ... overweight and obese adolescents with type 1 diabetes. ...
(Date:12/1/2015)... Russia has always been a country of choice for ... Europe in 2015 were tested in phase II-III ... has always been a country of choice for global multi-center phase ... in 2015 were tested in phase II-III clinical trials ... always been a country of choice for global multi-center phase III clinical ...
(Date:12/1/2015)... 1, 2015 Contraceptives ... Contraceptives, Male Condoms, Female Condoms, Intrauterine Devices, ... Diaphragms, Contraceptive Sponges, Non-Surgical Permanent Contraception Devices) ... Trends and Forecast 2014 - 2020 ", ... (TMR).The report states that the global contraceptives ...
Breaking Medicine Technology: